DUBLIN, May 24, 2022--(BUSINESS WIRE)--The "Facial Injectable Market Size, Share & Trends Analysis Report by Product (Collagen, Hyaluronic Acid, Botulinum Toxin Type A, Calcium Hydroxylapatite, Polymer Fillers), by Application (Aesthetic, Therapeutic), by Region, and Segment Forecasts 2022-2030" report has been added to ResearchAndMarkets.com's offering.
The global facial injectable market size is expected to reach USD 35.0 billion by 2030 and is expected to register a CAGR of 9.1% from 2022 to 2030
The facial injectable is a substance that is used to reduce wrinkles and restore volume and fullness in the face. It is injected beneath the facial skin surface. Some commonly used facial injectable include hyaluronic acid, botulinum toxin type A, and polymer fillers.
Growing focus on physical appearance, especially in developing countries is one of the key factors expected to drive the market. In addition, a shift in consumer preference towards minimally invasive procedures is also expected to support market growth.
According to the American Society of Plastic Surgeons (ASPS), in 2020, botulinum toxin A and soft tissue fillers were among the top 5 minimally invasive procedures carried out in the U.S. Thus, facial injectable holds high growth prospects in the years to come.
In Asia Pacific, the market is expected to serve as a key revenue-generating center. The region is backed by countries such as India, where a growing focus on physical appearance is expected to create a lucrative opportunity for the market. Companies such as Allergan are also expanding their presence in the country owing to the rise in the number of middle-class populations backed by increasing disposable income.
The onset of the pandemic led to nonurgent and cosmetic surgeries being put on hold in the first and second quarters of 2020. However, the later months witnessed high demand for aesthetic consultations and procedures as patients were willing to undergo cosmetic treatments now more than ever due to high disposable income and desire to look appealing on zoom calls and online meetings.
Facial Injectable Market Report Highlights
The botulinum toxin type A segment is projected to dominate the market throughout the forecast period. It is one of the most popularly used minimally invasive procedures.
The aesthetic segment is projected to grow fast over the forecast period owing to the rise in the use of facial injectables for aesthetic procedures such as the treatment of wrinkles on the face.
North America dominated the market with a revenue share of 41.0% IN 2021 owing to the easy availability of the products and the presence of a large number of skilled surgeons.
Chapter 3. Facial Injectable Market Variables, Trends & Scope
3.2. Penetration & Growth Prospect Mapping
3.4. Facial injectable: Market Analysis Tools
3.4.3. Major Deals & Strategic Alliances Analysis
Chapter 4. Facial Injectable Market: Segment Analysis, by Product, 2018-2030 (USD Million)
4.2. Product Market Share Analysis, 2022 & 2030
4.3. Global Facial Injectable Market, by product, 2018 to 2030
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
Chapter 5. Facial Injectable Market: Segment Analysis, by Application, 2018-2030 (USD Million)
5.2. Category Market Share Analysis, 2022 & 2030
5.3. Global Facial injectable Market, by Application, 2018 to 2030
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
Chapter 6. Facial Injectable Market: Regional Market Analysis, by Region, 2018-2030 (USD Million)
6.2. Regional Market Share Analysis, 2022 & 2030
6.3. Market Size, & Forecasts, and Trend Analysis, 2018 to 2030
Chapter 7. Facial Injectable Market-Competitive Analysis
Merz Pharma GmbH & Co. Kgaa
For more information about this report visit https://www.researchandmarkets.com/r/sbkk8y
View source version on businesswire.com: https://www.businesswire.com/news/home/20220524005769/en/
ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Shareholders in Amazon (NASDAQ: AMZN) beat a rising market on Friday morning, with shares gaining 3% by 10:45 a.m. ET compared to a 1.4% boost in the S&P 500. The rally was powered by a brightening outlook around economic growth and consumer spending. A major factor driving Amazon's stock higher on Friday was the boost in the wider tech world.
The Dow Jones rallied amid encouraging inflation data. Tesla stock jumped even as CEO Elon Musk issued a warning. Apple stock surged.
(Bloomberg) -- Fertilizer prices that had hit records are now plunging as buyers reel from sticker shock, but that doesn’t mean the market squeeze is over. Most Read from BloombergFord Beats Tesla to the Punch With First Electric F-150 DeliveryStocks Notch Their Best Week Since November 2020: Markets WrapRussian Wins in Eastern Ukraine Spark Debate Over Course of WarUkraine Latest: US Slams Putin’s Food-for-Sanctions Relief PlanZilingo’s Fired CEO Responds to Questions of Mystery PaymentsThe Jun
Stop investing in mediocre businesses. Buy the best, instead.
Stock splits have been all the rage in recent years, fueled by surging stock prices of some of the world's most recognizable companies. Worse still, the tech-heavy Nasdaq has tumbled into bear market territory, down roughly 27% from its high reached late last year. Read on to find out why they picked Amazon (NASDAQ: AMZN), Alphabet (NASDAQ: GOOGL) (NASDAQ: GOOG), and Shopify (NYSE: SHOP) from among the recent stock-split candidates.
Shares of Moderna (NASDAQ: MRNA) were jumping 7.5% higher as of 11:30 a.m. ET on Friday. Instead, Moderna appears to be benefiting from the overall stock market bounce. Good news for the overall stock market tends to be good news for Moderna.
Julian Bridgen, co-founder and president of Macro Intelligence 2 Partners, joins Yahoo Finance Live to discuss this week's market action and whether or not it will carry over into next week, the Fed, and inflation.
In this article, we discuss the 10 stocks that Jim Cramer and hedge funds agree on. If you want to read about some more stocks that Jim Cramer and hedge funds agree on, go directly to Jim Cramer and Hedge Funds Agree on These 5 Stocks. In the past few weeks, Jim Cramer, the journalist […]
Ulta shares are up after its big Q1 earnings beat, Aurora Cannabis increased its finance deal to $150 million, and Blackberry stock is surging after news of its partnership with Google.
Nikola (NASDAQ: NKLA) hasn't posted any significant news since it reported first-quarter earnings earlier this month. Early in Friday's trading session, Nikola shares were 19.6% higher for the week, according to data provided by S&P Global Market Intelligence. More than 20% of Nikola's outstanding shares were sold short, as of mid-May. And because a large number of those shares are held by company executives or in its treasury, 36.5% of Nikola's share float were being shorted by investors, according to MarketWatch.
Despite all the attention that renewable energy companies get, having operations in the renewable energy space alone does not make a stock a buy. In fact, several renewable energy companies are struggling just to stay profitable. Let's discuss two renewable energy stocks that look attractive right now, and one that's best avoided.
In this article, we will look at 10 undervalued stocks to buy according to billionaire Leon Cooperman. If you want to skip reading about Leon Cooperman’s early life, investment philosophy, and his hedge fund’s performance, you can go directly to 5 Undervalued Stocks to Buy According to Billionaire Leon Cooperman. Leon Cooperman is an American […]
Risk and reward are the yin and yang of stock trading, the two opposite but essential ingredients in every market success. And there are no stocks that better embody both sides – the risk factors and the reward potentials – than penny stocks. These equities, priced below $5 per share, typically offer high upside potentials. Even a small gain in share price – just a few cents – quickly translates into a high yield return. Of course, the risk is real, too; not every penny stock is going to show th
Qualcomm CEO Cristiano Amon weighs in on the outlook for the semiconductor industry and his company's future.
Some investors turned to nonfungible tokens in search of a haven among digital assets in the first quarter. However, the bets soon turned sour.
The cannabis company's per-share loss was almost five times as big as analysts had expected. The stock plunged in response.
Shares of Farfetch Limited (NYSE: FTCH), a luxury fashion e-commerce platform, spiked today after the company reported a better-than-expected loss in the first quarter. Farfetch reported an adjusted loss per share of $0.24 in the first quarter, which was down from a loss of $0.22 per share in the year-ago quarter but ahead of analysts' average estimate of a loss of $0.28 per share. "Our core business remains very strong, in spite of the macro events in China and ceasing operations in Russia, which impacted our performance and outlook," José Neves, Farfetch's founder and CEO, said in a press release.
Shares of Dutch Bros (NYSE: BROS) are rocketing higher this week, surging 34.1% compared to where they closed last Friday, according to data from S&P Global Market Intelligence, riding a meme stock wave of buying. After it was reported that short interest in the coffee shop shot up almost 30% in the latest period, stock traders who populate various internet stock chat rooms piled into the stock. Meme stocks, of course, are stocks that trade more on social media chatter than on business fundamentals, though in Dutch Bros' case the underlying business is pretty good, too.
A key measure of U.S. inflation rose just 0.2% in April to mark the smallest increase in a year and a half, aided by lower gas prices. Yet there were other hints that a surge in U.S. inflation might be abating.
The market is unstable. Your portfolio doesn’t need to be.